Fewer than 10% of people with symptomatic Alzheimer’s disease receive a diagnosis in the earliest stage. For most, diagnosis comes too late or not at all. Behind that number are families navigating one of the most difficult diseases imaginable, often without answers or a plan.
But science is changing. New advances in diagnosis and treatment are reshaping what’s possible for patients. A growing number of health systems are rethinking the entire ecosystem of care to make sure those innovations actually reach the people who need them.
Against the backdrop of the Clinical Trials on Alzheimer’s Disease Conference in Boston, join us virtually on Wednesday, November 18th at 6:00 PM ET for an evening with the clinicians and health system leaders at the forefront of that work.
If you are a licensed US Prescriber or a Health Care Provider licensed in a state with laws requiring payment disclosures, please be aware of Lilly’s transparency reporting requirements as a result of enacted federal and state legislation.
As a result of enacted state and federal legislation, if you are a prescriber or other licensed healthcare professional with an active license from MA, MN, NJ and/or VT, a Veterans Affairs employee, and/or a state or federal government employee, you may be restricted from accepting industry-provided food/beverage. Please consult your state or federal regulations or ethics laws.
